Daily Ocular Symptom Severity Score (DOSSS)
DOSSS was calculated as the mean symptom score across all ocular symptom
severity components daily (including itchy, watery, ore red eyes), each
scored by patients according to a 4-point scale (0, none; 1, mild; 2,
moderate; 3, severe). Four studies with 949 randomized patients provided
enough data to allow for a quantitative evidence synthesis based on the
DOSSS. Overall, omalizumab statistically significantly reduced the DOSSS
score by a summary standardized mean difference of -0.30 points (95%
CI, -0.50, -0.09; p=0.004; I2 = 86.2%) (Figure 3).